New combo therapy targets hard-to-treat thyroid cancer

NCT ID NCT07235566

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated Jun 16, 2026 · Updated 29 times

Summary

This study tests two drugs together—MRG003 and pucotenlimab—for people with a rare and aggressive type of thyroid cancer (ATC or PDTC) that has spread and cannot be removed by surgery. About 60 adults will receive the combination every three weeks. The main goal is to see if the treatment shrinks tumors. This is a phase II trial, meaning it is still being tested for safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China

Conditions

The condition(s) this trial relates to.

poorly differentiated thyroid gland carcinoma thyroid cancer thyroid gland undifferentiated (anaplastic) carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID CANCER